Trial Profile
A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO AND NAPROXEN CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 18 May 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary) ; Naproxen
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 03 Nov 2020 Results of a pooled analysis of data pooled from 6 trials assessing the relative efficacy and tolerability of 2.5, 5, and 10 mg tanezumab for the treatment of osteoarthritis published in the International Journal of Clinical Pharmacology and Therapeutics
- 23 Jun 2010 Status changed from recruiting to suspended, as requested by the US FDA due to reports of worsening osteoarthritis, according to a Pfizer media release.
- 15 Apr 2010 Planned end date changed from May 2010 to Jul 2010 as reported by ClinicalTrials.gov.